Revenue
2010
2011
Theriva Biologics, Inc. (TOVX)
Price—Loading quote
Net income
2017
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $2.6M |
| Research & development | $8.6M | $12.0M | $14.3M | $11.7M | $7.8M | $5.1M | $11.1M | $18.8M | $29.1M | $32.9M | $14.5M | $6.5M | $12.3M | $3.3M | $1.6M |
| Operating expenses | $24.1M | $26.3M | $21.4M | $21.6M | $14.3M | $10.2M | $15.7M | $26.3M | $39.3M | $41.0M | $20.5M | $12.3M | $17.3M | $5.9M | $3.7M |
| Operating income | −$24.1M | −$26.3M | −$21.4M | −$21.6M | −$14.3M | −$10.2M | −$15.7M | −$26.3M | −$39.3M | −$41.0M | −$20.5M | −$12.3M | −$17.3M | — | — |
| EBITDAderived | −$23.9M | −$26.2M | −$21.3M | −$21.5M | −$14.2M | −$10.0M | −$15.4M | −$26.0M | −$39.1M | −$40.9M | −$20.5M | −$12.3M | — | — | — |
| Net income | −$23.7M | −$25.7M | −$18.3M | −$19.7M | −$14.3M | −$10.0M | −$15.3M | −$15.2M | −$27.3M | −$43.7M | −$19.8M | −$12.3M | −$17.1M | −$8.1M | −$1.7M |
| Basic EPSper diluted share | -$2.08 | -$19.03 | -$28.48 | -$1.31 | -$1.90 | -$0.66 | -$0.98 | -$6.23 | -$0.29 | -$0.54 | -$0.32 | -$0.27 | -$0.49 | -$0.29 | -$0.08 |
| Diluted EPSper diluted share | -$2.08 | -$19.03 | -$28.48 | -$1.31 | -$1.90 | -$0.66 | -$0.98 | -$6.23 | -$0.29 | -$0.54 | -$0.32 | -$0.27 | -$0.49 | -$0.29 | -$0.08 |